Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective study based on propensity score matching
Objective Pseudomyxoma peritoneum (PMP) of appendiceal origin poses significant treatment challenges with hyperthermic intraperitoneal chemotherapy (HIPEC) regimens offering viable outcomes. This study aimed to compare the efficacy and safety profiles of two HIPEC regimens: cisplatin + docetaxel (CD...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | International Journal of Hyperthermia |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/02656736.2025.2467296 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850172384825311232 |
|---|---|
| author | Yu-Bin Fu Rui Yang Yan-Dong Su Ru Ma Tian Wei Yang Yu Bing Li Yan Li |
| author_facet | Yu-Bin Fu Rui Yang Yan-Dong Su Ru Ma Tian Wei Yang Yu Bing Li Yan Li |
| author_sort | Yu-Bin Fu |
| collection | DOAJ |
| description | Objective Pseudomyxoma peritoneum (PMP) of appendiceal origin poses significant treatment challenges with hyperthermic intraperitoneal chemotherapy (HIPEC) regimens offering viable outcomes. This study aimed to compare the efficacy and safety profiles of two HIPEC regimens: cisplatin + docetaxel (CD) and cisplatin + mitomycin C (CM).Methods PMP patients who underwent cytoreductive surgery (CRS) and HIPEC between January 2008 and December 2023 at our center were retrospectively analyzed. Patients were divided into CD and CM groups and matched for baseline characteristics using propensity score matching (PSM). Clinicopathological data, efficacy, and safety profiles were compared. Univariate and multivariate analyses identified independent prognostic factors, and subgroup analyses further compared the two regimens.Results After PSM, 104 patients met the inclusion criteria (52 in each group). The median overall survival (mOS) was significantly longer in the CD group (156.3 vs. 60.9 months, p = 0.018), with no significant differences in adverse event severity between groups. Multivariate analysis identified HIPEC regimen, completeness of cytoreduction (CC), and pathological type as independent prognostic factors. Subgroup analysis showed significant mOS benefit for the CD regimen in patients with peritoneal carcinomatosis index (PCI) ≥ 27, CC 2/3, high grade pathology, tumor markers ≥1 evaluated and BMI < 25 (all p < 0.005).Conclusions Following CRS, the CD regimen offers superior survival benefits compared to the CM regimen for PMP patients. These findings highlight the potential of personalized HIPEC strategies to optimize outcomes for PMP treatment. |
| format | Article |
| id | doaj-art-22d54be1ebb44ca2b6ec430a786531fb |
| institution | OA Journals |
| issn | 0265-6736 1464-5157 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | International Journal of Hyperthermia |
| spelling | doaj-art-22d54be1ebb44ca2b6ec430a786531fb2025-08-20T02:20:06ZengTaylor & Francis GroupInternational Journal of Hyperthermia0265-67361464-51572025-12-0142110.1080/02656736.2025.2467296Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective study based on propensity score matchingYu-Bin Fu0Rui Yang1Yan-Dong Su2Ru Ma3Tian Wei4Yang Yu5Bing Li6Yan Li7Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaDepartment of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaDepartment of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaDepartment of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaDepartment of Surgical Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, ChinaDepartment of Surgical Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, ChinaDepartment of Surgical Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, ChinaDepartment of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaObjective Pseudomyxoma peritoneum (PMP) of appendiceal origin poses significant treatment challenges with hyperthermic intraperitoneal chemotherapy (HIPEC) regimens offering viable outcomes. This study aimed to compare the efficacy and safety profiles of two HIPEC regimens: cisplatin + docetaxel (CD) and cisplatin + mitomycin C (CM).Methods PMP patients who underwent cytoreductive surgery (CRS) and HIPEC between January 2008 and December 2023 at our center were retrospectively analyzed. Patients were divided into CD and CM groups and matched for baseline characteristics using propensity score matching (PSM). Clinicopathological data, efficacy, and safety profiles were compared. Univariate and multivariate analyses identified independent prognostic factors, and subgroup analyses further compared the two regimens.Results After PSM, 104 patients met the inclusion criteria (52 in each group). The median overall survival (mOS) was significantly longer in the CD group (156.3 vs. 60.9 months, p = 0.018), with no significant differences in adverse event severity between groups. Multivariate analysis identified HIPEC regimen, completeness of cytoreduction (CC), and pathological type as independent prognostic factors. Subgroup analysis showed significant mOS benefit for the CD regimen in patients with peritoneal carcinomatosis index (PCI) ≥ 27, CC 2/3, high grade pathology, tumor markers ≥1 evaluated and BMI < 25 (all p < 0.005).Conclusions Following CRS, the CD regimen offers superior survival benefits compared to the CM regimen for PMP patients. These findings highlight the potential of personalized HIPEC strategies to optimize outcomes for PMP treatment.https://www.tandfonline.com/doi/10.1080/02656736.2025.2467296Pseudomyxoma peritoneicytoreductive surgeryhyperthermic intraperitoneal chemotherapy regimensoverall survivalserious adverse events |
| spellingShingle | Yu-Bin Fu Rui Yang Yan-Dong Su Ru Ma Tian Wei Yang Yu Bing Li Yan Li Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective study based on propensity score matching International Journal of Hyperthermia Pseudomyxoma peritonei cytoreductive surgery hyperthermic intraperitoneal chemotherapy regimens overall survival serious adverse events |
| title | Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective study based on propensity score matching |
| title_full | Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective study based on propensity score matching |
| title_fullStr | Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective study based on propensity score matching |
| title_full_unstemmed | Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective study based on propensity score matching |
| title_short | Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective study based on propensity score matching |
| title_sort | cisplatin docetaxel improves survival over cisplatin mitomycin c in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei a retrospective study based on propensity score matching |
| topic | Pseudomyxoma peritonei cytoreductive surgery hyperthermic intraperitoneal chemotherapy regimens overall survival serious adverse events |
| url | https://www.tandfonline.com/doi/10.1080/02656736.2025.2467296 |
| work_keys_str_mv | AT yubinfu cisplatindocetaxelimprovessurvivalovercisplatinmitomycincinhyperthermicintraperitonealchemotherapyforpseudomyxomaperitoneiaretrospectivestudybasedonpropensityscorematching AT ruiyang cisplatindocetaxelimprovessurvivalovercisplatinmitomycincinhyperthermicintraperitonealchemotherapyforpseudomyxomaperitoneiaretrospectivestudybasedonpropensityscorematching AT yandongsu cisplatindocetaxelimprovessurvivalovercisplatinmitomycincinhyperthermicintraperitonealchemotherapyforpseudomyxomaperitoneiaretrospectivestudybasedonpropensityscorematching AT ruma cisplatindocetaxelimprovessurvivalovercisplatinmitomycincinhyperthermicintraperitonealchemotherapyforpseudomyxomaperitoneiaretrospectivestudybasedonpropensityscorematching AT tianwei cisplatindocetaxelimprovessurvivalovercisplatinmitomycincinhyperthermicintraperitonealchemotherapyforpseudomyxomaperitoneiaretrospectivestudybasedonpropensityscorematching AT yangyu cisplatindocetaxelimprovessurvivalovercisplatinmitomycincinhyperthermicintraperitonealchemotherapyforpseudomyxomaperitoneiaretrospectivestudybasedonpropensityscorematching AT bingli cisplatindocetaxelimprovessurvivalovercisplatinmitomycincinhyperthermicintraperitonealchemotherapyforpseudomyxomaperitoneiaretrospectivestudybasedonpropensityscorematching AT yanli cisplatindocetaxelimprovessurvivalovercisplatinmitomycincinhyperthermicintraperitonealchemotherapyforpseudomyxomaperitoneiaretrospectivestudybasedonpropensityscorematching |